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Abstract
Microglia are the resident macrophages of the central nervous system (CNS). In
physiological conditions, resting microglia maintain tissue integrity by scanning
the entire CNS parenchyma through stochastic and complex movements of their
longprocessestoidentifyminortissuealterations.Inpathologicalconditions,over-
activatedmicrogliacontributetoneuronaldamagebyreleasingharmfulsubstances,
includinginﬂammatorycytokines,reactiveoxygenspecies,andproteinases,butthey
canprovidetissuerepairbyreleasinganti-inﬂammatorycytokinesandneurotrophic
factors. The reasons for this apparent paradox are unknown. In this paper, we ﬁrst
review the physiological role as well as both detrimental and beneﬁcial actions of
microglial during acute CNS disorders. Further, we discuss the possible reasons for
thismicroglialdualrolefollowingCNSinsults,consideringthattheﬁnalmicroglial
phenotype is a direct consequence of both noxious and beneﬁcial stimuli released
intotheextracellularspaceduringthepathologicalinsult.Thenatureofthesemicro-
glial ligands is unknown, but we hypothesize that harmful and beneﬁcial stimuli
may be preferentially located at speciﬁc anatomical niches along the pathological
environment triggering both beneﬁcial and deleterious actions of these glial cells.
Accordingtothisnotion,therearenonaturalpopulationsofdetrimentalmicroglia,
butisthepathologicalenvironmentthatdeterminestheﬁnalmicroglialphenotype.
Introduction
Microglia are believed to derive from monocytes that invade
thedevelopingcentralnervoussystem(CNS)andpersistover
the adult life as resident macrophages (Alliot et al. 1999).
A recent study using fate-mapping analysis conﬁrmed that
these glial cells derive from primitive myeloid progenitors
that arise before embryonic day 8 (Ginhoux et al. 2010) and
that postnatal hematopoietic progenitors do not contribute
to microglia homeostasis in the adult brain. These cells per-
form a multitude of physiological roles in normal adult CNS
(Nimmerjahn et al. 2005; Ransohoff and Perry 2009) and are
believed to perform both detrimental and beneﬁcial actions
during acute and chronic neural disorders (Block et al. 2007;
Perryetal.2010).Inphysiologicalconditions,theystochasti-
cally move their processes in several directions in a complex
way and scanning for minor tissue alterations for maintain-
ing tissue integrity (Stence et al. 2001; Davalos et al. 2005;
Nimmerjahn et al. 2005). Nevertheless, there is experimental
evidence suggesting that activated microglia perform both
beneﬁcial and detrimental actions after CNS disorders in-
cluding spinal cord injury (SCI), stroke, multiple sclerosis,
amyotrophic lateral sclerosis, prion, Parkinson, Huntington,
and Alzheimer diseases (Block et al. 2007; Ekdahl et al. 2009;
Perry et al. 2010).
Why do microglia have a dual role after CNS diseases?
There is not a deﬁnitive answer to this question. In this pa-
per, we ﬁrst review the dual role of microglia during acute
CNS disorders. Further, we discuss the possible reasons for
this duality under pathological conditions. We hypothesize
thatbothharmfulandbeneﬁcialstimuliarereleaseduponin-
jury into speciﬁc anatomical niches along the damaged areas
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triggering both beneﬁcial and deleterious actions of mi-
croglia. Depending on the CNS-affected area and disease’s
etiology, both noxious and beneﬁcial microglial phenotypes
might coexist along the pathological environment. Accord-
ing to this notion, there are no natural populations of dele-
terious microglia, but is the pathological environment that
determines the microglial phenotype.
The Physiological Roles of Microglia
Microglia patrol the adult CNS environment
in physiological conditions
In the mature CNS, microglia adopt a highly ramiﬁed mor-
phology under physiological conditions (Nimmerjahn et al.
2005). A study using confocal time-lapse analysis in hip-
pocampal slices ﬁrst has shown that microglia branches are
highly dynamic structures upon activation (Stence et al.
2001). Further, two-photon laser scanning microscopy al-
lowed visualization of ﬂuorescent resting microglia in the
brain of alive animals, showing that these glial cells continu-
ouslypatroltheCNSparenchymaseveraltimesadaythrough
stochastic movements of their long and ﬁne branches main-
tainingtissueintegrity(Davalosetal.2005;Nimmerjahnetal.
2005). Under physiological conditions, there exist mecha-
nismsassuringthatmicroglialcellsdonotdeveloppatternsof
activation with undesirable consequences for CNS integrity
(Bessis et al. 2007; Ransohoff and Perry 2009).
Neurons control microglial function by physical contact
or by releasing neurotransmitters, peptides and/or growth
factors including gamma-aminobutyric acid (GABA), gluta-
mate, catecholamines, CD22, CCL21, fraktalkine, which act
on receptors present on microglia membrane (Bessis et al.
2007). It has been shown that in organotypic hippocampal
culturesactiveneuronsreleaseneurotrophins,suchasneural
growth factor (NGF), which control the expression of major
histocompatibilityclassII(MHC-II)inmicrogliabyacting,at
least partially, on the p75 neurotrophin receptor (Neumann
et al. 1998). Neuronal secretion of CD22 inhibits microglial
release of pro-inﬂammatory cytokines by acting on CD45
receptor (Mott et al. 2004) and expression of CD200 may be
important for controlling tumor necrosis factor-α (TNF-α)
released by these glial cells (Broderick et al. 2002; Lyons et al.
2007). Finally, physical interaction between neuronal CD200
and CD200R present on microglia membrane likely repre-
sents an alternative way by which neurons can control mi-
croglialfunction(Brodericketal.2002;Lyonsetal.2007).Mi-
croglia also express a number of neurotransmitter receptors
indicating that activity-related release of neurotransmitters
by neurons contribute for microglial control in physiological
conditions (Bessis et al. 2007). These data clearly illustrate
the necessity of controlling both inﬂammatory and immune
microglial functions in physiological conditions in order to
maintain the integrity of CNS circuits.
Microglia and Adult Neurogenesis
New neurons are generated in the adult brain from neu-
ral stem/progenitor cells present in the subventricular zone
(SVZ) (Doetsch et al. 1997; Alvarez-Buylla and Garcia-
Verdugo2002)andsubgranularzoneofhippocampaldentate
gyrus (Seri et al. 2001). Microglia seem to play an impor-
tant physiological role of controlling adult neurogenesis in
normal conditions (Aarum et al. 2003; Walton et al. 2006;
Ekdahletal.2009).Invitro,mouse-derivedmicrogliarelease
soluble factors, which contribute to migration and differ-
entiation of neural progenitors (Aarum et al. 2003; Walton
et al. 2006). Microglia instruct neurogenesis in adult SVZ
in culture (Walton et al. 2006). In adherent culture systems,
there is a normal senescence and decrease in the number of
progenitor cells (Walton et al. 2006). This is coincident with
decreased numbers of microglial cells (Walton et al. 2006).
Xanthosine treatment results in extended microglia lifespan,
concomitant with increased neurogenic potential of SVZ-
derivedcells(Waltonetal.2006).Inthisexperimentalcondi-
tion, a MAC-1-saporin antibody, which depletes microglia,
decreases neurogenic potential, while microglia-conditioned
medium restores neurogenesis (Walton et al. 2006). A re-
cent in vivo study suggests that microglia contribute to hip-
pocampal neurogenesis in adrenalectomized rats (Battista
et al. 2006). In this study, the number of activated microglia
displaying a more ramiﬁed morphology, not full phagocytes,
correlatedwithincreasedneurogenesisandnumberofnestin-
positive cells (Battista et al. 2006). Nevertheless, the role of
microglia on adult neurogenesis is an open question. Exper-
imental depletion of SVZ microglia using a Mac-1 antibody
conjugated to saporin did not affect numbers and prolifera-
tion of migrating neuroblasts in the SVZ in nonpathological
conditions or migration of neuroblasts after striatal stroke
(Heldmann et al. 2011).
Several other functions are performed by microglia. A de-
tailed discussion of microglial functions can be obtained in
Ransohoff and Perry (2009).
Microglia Activation and Acute CNS
Disorders
Morphological and molecular correlates of
microglia activation
Microglia are extremely sensible to minor alterations on the
CNS microenvironment, even ionic disbalance and stress
(Kreutzberg 1996; Sugama et al. 2007; Ransohoff and Perry
2009). These cells are activated in pathological conditions,
which is reﬂected in both morphological and biochemical
alterations on their structure (Streit et al. 1999; Ransohoff
and Perry 2009). Microglia activation involves a conspicu-
ous change in their ramiﬁed morphology to an intermediate
and amoeboid form culminating in a round morphological
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proﬁle of full phagocytes (Morioka et al. 1993; Lehrmann
et al. 1997; Thored et al. 2009). Concomitant with morpho-
logical alterations, microglial cells change their genetic ma-
chinery and upregulate several transcription factors (for ex-
ample,NF-κB),cytoplasmicandsurfacemoleculesincluding
MHC classes I and II, complement C3, Fc, thrombin, scav-
enger receptors (i.e., CD36, SR-A, CD204, SR-BI), cytokine,
chemokine, CD4 and CD8 receptors, toll-like receptors, and
several oxidative enzymes, such as NADPH oxidase (Perry
and Gordon 1987; Schroeter et al. 1994; Jander et al. 1998;
Streit et al. 1999; Husemann et al. 2002; Block et al. 2007;
Ransohoff and Perry 2009).
An important question is which signals activate microglia
in the event of tissue damage. These mechanisms are not
completelyclear.Nevertheless,thereisexperimentalevidence
suggesting that the release of purine nucleotides, including
ATP, ADP, and UTP, by injured neurons is an important
mechanism by which microglia are informed of tissue in-
jury (Davalos et al. 2005; Nimmerjahn et al. 2005). These
nucleotides seem to act on P2Y receptors in both microglia-
and astrocytes-mediating chemotactic response of microglia
branches (Davalos et al. 2005; Nimmerjahn et al. 2005). In
addition, activation of connexin hemichannels in astrocytes
seems to mediate ampliﬁcation of the phenomenon by in-
ducing a continuous release of purine nucleotides by these
glial cells, which is fundamental for directing microglial pro-
cesses to the injury site (Davalos et al. 2005; Nimmerjahn
et al. 2005).
Beneﬁcial actions of microglia after CNS
diseases
Activated microglia can be beneﬁcial in several experimental
modelsofCNSdiseases(Neumannetal.2006;Schwartzetal.
2006;Lalancette-Hebertetal.2007;Thoredetal.2009).After
experimentalaxotomyoffacialnerve,thereismicroglialacti-
vation inside facial motor nucleus (Graeber et al. 1988; Streit
2002). Microglia clearly play a beneﬁcial role contributing to
reinnervation of target muscles (Graeber et al. 1988; Streit
2002). In this experimental paradigm, a regeneration pro-
graminvolvingmicroglialproliferationandactivationistrig-
gered resulting in the most conspicuous example of a neuro-
protective role of microglia after nervous system damage
(Streit 2002).
Microglia play a proregenerative role after SCI. Engraft-
mentofculturedmicroglialcellsintolesionedspinalcordin-
duces axonal sprouting (Rabchevsky and Streit 1997). In this
experimental condition, transplanted microglial cells seem
to release growth factors, which contribute to axonal regen-
eration (Rabchevsky and Streit 1997). It has been proposed
by Schwartz and colleagues that microglia/macrophages can
be highly neuroprotective after SCI and other CNS diseases
(Rapalino et al. 1998; Bomstein et al. 2003; Schwartz et al.
2006).Accordingtotheseauthors,neuroprotectivemicroglia
can express markers of antigen-presenting cells, including
MHC-class II and B7.2, which allow interactions with lym-
phocyte with subsequent release of growth factors rendering
a more amenable environment for neural regeneration (Bu-
tovskyetal.2001;Bomsteinetal.2003;Schwartzetal.2006).
Recent experimental evidences suggest that activated mi-
crogliamaybehighlyneuroprotectiveafterstroke(Neumann
et al. 2006, 2008; Lalancette-Hebert et al. 2007). Application
ofBV2microgliaisneuroprotectiveafteroxygen–glucosede-
privation in organotypic hippocampal slice cultures (Neu-
mannetal.2006).Usingthree-dimensional(3D)two-photon
microscopy, these authors have shown that transplanted mi-
croglia engage in physical contact with neurons in damaged
area, protecting them in the experimental circumstances. In
addition, blockage of microglia activation with minocycline
impairstheneuroprotectionafforded(Neumannetal.2006).
Using transgenic mice in which selective ablation of prolif-
erating microglia is feasible, Lalancette-Hebert et al. (2007)
have shown that microglia is clearly neuroprotective after
middle cerebral artery occlusion (MCAO). After microglial
ablation, there was an increase in the number of apoptotic
cellsconcomitantwithincreasedproinﬂammatorymolecules
(Lalancette-Hebert et al. 2007). In this study, Mac-2+ resi-
dent microglia release the proneurogenic molecule insulin-
like growth factor (IGF-1), which likely contribute to the
microglia-inducedneuroprotection(Lalancette-Hebertet al.
2007).Recentstudiessuggestthatmicrogliamaybebeneﬁcial
byengulﬁngneutrophils(Neumannetal.2008)andreleasing
TNF-α (Lambertsen et al. 2009) after ischemia. In addition,
microglia may be beneﬁcial through their phagocytic func-
tions.Somestudiessuggestthatphagocytosisofinjuredtissue
is important for remodeling and may limit secondary dam-
age following brain hemorrhage (Zhao et al. 2007). Recent
studies suggest that microglia may shape hippocampal adult
neurogenesis by clearing out apoptotic newborn cells, which
illustrates the important phagocytic function of microglia
(Sierra et al. 2010).
Recently, we have shown that there is long-lasting mi-
croglial activation with a proneurogenic phenotype in SVZ
afterstroke(Thoredetal.2009).TheseglialcellsreleaseIGF-
1inlatesurvivaltimesafterstroke,whichhasbeenconﬁrmed
by affymetrix analysis and quantitative polymerase chain re-
action (PCR) (Thored et al. 2009). The results indicate that
long-term activation of microglia in SVZ after stroke is im-
portant for regulating the previously described long-lasting
neurogenesis in SVZ (Thored et al. 2006).
Detrimental actions of microglia after CNS
diseases
There is clear experimental evidence suggesting that over-
activated microglia may be extremely detrimental following
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acute neural disorders, including SCI (Popovich et al. 1999,
2002; Gomes-Leal et al. 2005; Kigerl et al. 2009) and stroke
(Yrjanheikki et al. 1999; Yong et al. 2004; Hewlett and Cor-
bett2006;Hayakawaetal.2008;Schabitzetal.2008;Wuetal.
2009; Fagan et al. 2010).
Depletion of hematogenous macrophages with clodronate
induces partial hindlimb recovery and neuroprotection af-
ter acute SCI (Popovich et al. 1999). Microglia/macrophage
activation seems to contribute to axonal damage following
experimental injection of N-methyl-d-Aspartate (NMDA)
(Gomes-Leal et al. 2005) and zymosan (Popovich et al.
2002) into the rat spinal cord. The semisynthetic tetra-
cycline minocycline, an inhibitor of microglial activation,
reduces secondary oligodendrocyte and axonal degeneration
as well as modulates apoptosis after SCI (Stirling et al. 2004)
and cell cycle inhibition attenuates microglia-induced in-
ﬂammatoryresponseanddecreasescelldeathafterSCI(Tian
et al. 2007). In addition, mild hypothermic treatment re-
ducesspinalcordmotordysfunctionbydecreasingmicroglia
activation (Morino et al. 2008).
Blockage of microglial activation with minocycline in-
duces conspicuous neuroprotection in both cortex and stria-
tum after experimental rat MCAO (Yrjanheikki et al. 1999).
Recent studies have conﬁrmed that minocycline has a po-
tent neuroprotective effect after ischemia by inhibiting a
cytokine-like mediator (high-mobility group box 1) in mi-
croglia(Hayakawaetal.2008).Nevertheless,itisimportantto
bear in mind that minocycline has other pleiotropic actions,
including matrix metalloproteinases-9 (MMP-9) inhibition,
PARP or NFκB, scavenging of peroxynitrite, upregulation of
bcl-2, and may affect cells other than microglia (Yong et al.
2004; Kim and Suh 2009). Other microglial inhibitors ren-
der neuroprotection after stroke. PJ34, a potent poly(ADP-
ribose) polymerase inhibitor, abolishes microglial activation
and reduces hippocampal neuronal death by 84% if admin-
istered at 8 h after 10 min of global forebrain ischemiain rats
(Hamby et al. 2007). Patients with acute stroke had a better
neurological outcome with minocycline treatment (Lampl
et al. 2007; Schabitz et al. 2008; Fagan et al. 2010). Recent in
vitroandinvivostudiessuggestthattheneurotoxicactionsof
microglia during ischemiaare mediated by microglialtype II
metabotropicreceptors,TNF-αoverproduction,NF-κBacti-
vation (Kaushal and Schlichter 2008), and Nox-1-dependent
NADPH oxidase (Cheret et al. 2008). In addition, it has been
reported that caspase activation is an important mechanism
underlyingthedeleteriousfunctionsofmicroglia(Burguillos
et al. 2011).
There are experimental evidences that microglial activa-
tionisdetrimentalforadultneurogenesisindifferentmodels
of CNS injury (Ekdahl et al. 2003; Monje et al. 2003; Hoehn
etal.2005;Liuetal.2007).Microglialactivationimpairsbasal
hippocampal adult neurogenesis induced by tissue damage
associatedwithstatusepilepticusorlipopolysaccharide(LPS)
infusion (Ekdahl et al. 2003). The impaired adult neuro-
g e n e s i si sr e s t o r e da f t e rm i c r o g l i a lb l o c k a g eu s i n gm i n o c y -
cline (Ekdahl et al. 2003). Minocycline or indomethacin
treatment also enhances adult neurogenesis after MCAO in
rodents (Hoehn et al. 2005; Liu et al. 2007).
How to Explain the Dual Role of
Microglia after CNS Diseases?
We have seen that microglia have important physiological
functions on the normal CNS and a dual role after neu-
ral disorders. How to explain this apparent paradox? In the
following paragraphs, based on experimental evidences, in-
cludingourowndata,weproposeahypothesistoexplainthe
dual role of microglia after CNS diseases.
Microgliaarefundamentalcomponentsofbraininnateim-
mune system responsible for protecting neural tissue against
infections(OlsonandMiller2004;Townetal.2005;Lehnardt
2010).Toperformsucharole,microgliamonitortheCNSen-
vironmentusingmembranemoleculescalled“patternrecog-
nition receptors” (PRRs) (Akira et al. 2006). These PRRs
include toll-like receptors (Olson and Miller 2004; Downes
andCrack2010),scavengerreceptors(Husemannetal.2002),
and the complement receptor 3 Mac1 (Ross 2000).
During CNS infection, PRRs interact with pathogen-
associated molecular patterns (PAMPs) in the membrane
of infectious agents, which triggers the release of pathogen-
killer molecules by microglia, including hydrogen peroxide,
NO, O2
−, peroxynitrite, and a range of pro-inﬂammatory
molecules such as prostaglandin E2, IL-1β, and TNF-α (Ol-
son and Miller 2004; Block et al. 2007; Buchanan et al. 2010;
Downes and Crack 2010; Lehnardt 2010). A main down-
stream event following pathogen recognition by microglia
is the activation of NADPH-oxidase, which is a fundamen-
tal step for free radical release and other pro-inﬂammatory
microglial actions (Block and Hong 2005; Qin et al. 2005;
Cheret et al. 2008). This is a physiological and an appro-
priate response of microglia in order to eliminate pathogens
andpreservetissueintegrity.Nevertheless,recentstudiessug-
gest that in noninfectious diseases, such as stroke, SCI, and
chronicneurodegenerativediseases,microgliamightmistake
noninfectious disease-associated stimuli for the ones associ-
ated with infectious diseases, activating their killing mecha-
nisms, which normally would be used to kill pathogens, but
are unintentionally used to kill neurons (Block et al. 2007;
Grifﬁths et al. 2007).
It has been suggested that PRR activation underlies the
mechanisms of cell demise in a number of noninfectious
neural and nonneural diseases (Karin et al. 2006; Town et al.
2006; Grifﬁths et al. 2007; Lehnardt et al. 2007; Ziegler et al.
2007). For example, TLR-2 mediates CNS injury in focal
cerebral ischemia (Lehnardt et al. 2007) and activation of
TLR-4 by a speciﬁc type of heat shock protein may be an
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endogenous molecular pathway common to many forms of
neuronal injury (Lehnardt et al. 2008). TLR4 and CD14 are
the primary LPS receptors in microglia (Lien et al. 2000) and
inseveralexperimentalcircumstancesLPSinducesmicroglia
activation with neurotoxic consequences (Ling et al. 2006;
Peietal.2007;Qinetal.2007).Activationofothermicroglial
PRRs is also involved in neurodegeneration (Cho et al. 2005;
Blocketal.2007;Peietal.2007).Theseandotherresultssug-
gest that noninfectious stimuli might bind microglial PRRs
activating their killing mechanisms, which normally would
be used to kill pathogens, but are unintentionally used to kill
neurons in noninfectious CNS diseases (Block et al. 2007;
Grifﬁths et al. 2007).
From the experimental data described above, it is possible
to infer that microglia are beneﬁcial neuroimmune cells that
might become detrimental in pathological conditions. It is
likely that during neural disorders, a mosaic of detrimental
and beneﬁcial stimuli are released by altered neurons, glia,
blood vessels, and other sources into the extracellular space,
and microglial cells interpret them by using their surface
receptors. We hypothesize that these harmful and beneﬁ-
cial stimuli are released into speciﬁc anatomical niches along
damaged areas triggering both beneﬁcial and deleterious ac-
tions of microglia. Depending on the CNS-affected area and
disease’setiology,bothnoxiousandbeneﬁcialmicroglialphe-
notypes might coexist along the pathological environment.
According to this notion, there are no natural populations
ofdeleteriousmicroglia,butisthepathologicalenvironment
that determines the ﬁnal microglial phenotype. We have rea-
sons to suppose that this phenomenon occurs after stroke
and other neural disorders. We will present experimental
evidences to substantiate this hypothesis in the following
paragraphs.
In a recent study, we have described different patterns of
microglialactivationoverweeksafterMCAOinbothSVZand
striatum (Thored et al. 2009). In SVZ, microglia exhibited
a more ramiﬁed or intermediate morphology, signifying a
downregulated inﬂammatory proﬁle, whereas amoeboid or
round phagocytic microglia were frequent in the periinfarct
striatum (Thored et al. 2009). In this study, SVZ microglia
seem to be proneurogenic as they upregulate expression of
IGF-1, a growth factor known to be neurogenic in different
experimental conditions (Yan et al. 2006).
In the striatum of the same experimental animals, ac-
tivated microglia were more activated and often amoe-
boid and round at two weeks after MCAO (Thored et al.
2009). These results suggest that microglia activation is dif-
ferentially regulated in SVZ and striatum. The neurogenic
niche seems to modulate microglia function toward a more
neuroprotective/neurogenic phenotype. Gradients of both
anti-inﬂammatory cytokines and growth factors inside SVZ
might be involved. These results illustrate well how mi-
croglial phenotype may be inﬂuenced by the molecular con-
stitution of different anatomical niches along the ischemic
environment.
We have reasons to believe that both beneﬁcial and detri-
mental microglia are present in different anatomical niches
after MCAO. In an ongoing investigation, we have observed
that clustered SVZ microglia were spatially associated with
clusters of neuroblasts several weeks after MCAO (Fig. 1).
In addition, we have observed zones of abnormal aggre-
gate (clustering) of hyperactivated microglia/macrophages
(round and/amoeboid cells) as well as nonoverlapping re-
gions of microglia displaying an intermediate morphology
in the ischemic striatum weeks after MCAO (Fig. 2). Dou-
ble immunoﬂuorescence for Iba1 (a microglia marker) and
DCX (a neuroblast marker) revealed a surprising spatial cor-
relation between these two cell populations in both SVZ and
ischemic striatum. A few neuroblasts were present inside ab-
normal striatal microglial aggregations (Fig. 2A–C), which
suggest that this anatomicalniche is comprised by detrimen-
tal microglia/macrophages contributing to neuroblast death
or impairing their survival. Nevertheless, in the striatal re-
gions outside aggregations, which contain microglia with
a more intermediate morphology, neuroblasts were inter-
mingled with microglia (Fig. 2D–I) prompting us to believe
in a proneurogenic role for microglia in these anatomical
niches.
Based on the experimental evidence described, we pro-
pose that detrimental (overactivated) and beneﬁcial (inter-
mediately activated) microglia might be present in discrete
anatomical niches along the ischemic environment. Inhibi-
tion of stroke-induced microglia clustering formation, with-
out avoiding intermediate (more physiological) levels of mi-
croglia activation can be a promising experimental approach
for future investigations.
Microglia with different phenotypes in discrete anatom-
ical niches along the pathological environment seem to be
present in other experimental conditions, including chronic
neurodegenerative diseases (Block et al. 2005; Battista et al.
2006; Fendrick et al. 2007). Activated microglia displaying a
more ramiﬁed morphological proﬁle (not amoeboid or full
phagocytes) were reported to modulate hippocampal neuro-
genesis in adrenalectomized rats (Battista et al. 2006). Mi-
croglial/macrophages aggregates were also suggested to be
neurotoxicinamousemodelofamyotrophiclateralsclerosis
(ALS) (Fendrick et al. 2007). In these experimental circum-
stances, formation of multinucleated giant cells seems to be
highlydetrimental.Normalappearingmicrogliawerepresent
in other anatomical regions displaying less tissue damage
(Fendrick et al. 2007). It is possible that microglia become
multinucleate giant cells, fusing their membranes and re-
leasing neurotoxins exacerbating tissue loss, when in aggre-
gation. Macrophage aggregations are sites of overactivated
and potentially neurotoxic microglia and a feature of sev-
eral CNS diseases, including stroke, trauma, HIV infection
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Figure 1. Spatial correlation between activated microglia and migrating neuroblasts in the subventricular zone (SVZ) after middle cerebral artery
occlusion (MCAO). Microglia were labeled by anti-Iba1 (green) and migrating neuroblasts by antidoublecortin (red) double immunoﬂuorescence.
Ramiﬁed microglia were spatially associated with migrating neuroblasts in early (A–C) and late survival times (D–F) after MCAO. lv, lateral ventricle; st,
striatum. Scale bar = 200 μm.
associated dementia, and ALS (Block and Hong 2005). Nev-
ertheless, studies using a model of prion disease (Perry et al.
2007) have indicated that microglia can switch to a pheno-
type contributing to neuronal damage without morpholog-
ical changes (Perry et al. 2007). Thus, in some experimental
models of CNS disease there is no direct correlation between
morphological proﬁle and functional phenotype.
Different stimuli acting on different microglial receptors
may render different microglial phenotypes after CNS dis-
eases. Schwartz and colleagues have shown that it is the type
of stimulus that determines the microglial phenotype (Bu-
tovsky et al. 2005; Schwartz et al. 2006). LPS or amyloid-
β induces a detrimental microglial phenotype by inducing
these cells to release great amounts of TNF-α and NO, while
low doses of interferon gamma or the anti-inﬂammatory
cytokine IL-4 induces a beneﬁcial proﬁle in microglia man-
ifested by release of growth factors, including brain-derived
neurotrophicfactor(BDNF)andIGF-1(Butovskyetal.2005;
Schwartz et al. 2006). In vivo, macrophages stimulated by
tissues with known regenerative capacity, for example sci-
atic nerve (Rapalino et al. 1998) or skin (Bomstein et al.
2003),acquireaneuroprotectiveproﬁle.Intheseexperimen-
tal conditions, the environmental stimuli, such as growth
factors,mightbindtosurfacemicroglialreceptors,activating
intracellular biochemical pathways favoring physiological-
neuroprotectiveactions.Thishassimilaritiestowhathappens
in peripheral tissues, in which macrophages can be pheno-
typically polarized by the microenvironment to perform dif-
ferent functions (Martinez et al. 2008). In peripheral tissues,
macrophages can be classiﬁed in two main groups: classi-
cally activated macrophages (M1) and alternatively activated
macrophages(M2).M1macrophagesaremainlyactivatedby
interferon gamma and LPS, while M2 after exposure to IL-4,
IL-13, TGF beta or glucocorticoids (Martinez et al. 2008). In
noninfectious conditions, M2-polarized macrophages play a
roleinresolutionofinﬂammationthroughphagocyticmech-
anisms and by releasing growth factors, accompanied by re-
duced pro-inﬂammatory cytokine secretion (Martinez et al.
2008).Itispossiblethatspeciﬁcligandscanpolarizemicroglia
to different phenotypes like in the periphery (Durafourt
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Figure 2. Spatial correlation between activated microglia and migrating neuroblasts in the striatum after middle cerebral artery occlusion (MCAO).
Microglia were labeled by anti-Iba1 (green) and migrating neuroblasts by antidoublecortin (red) doubleimmunoﬂuorescence.Aggregations(
∗clustering)
of overactivated microglia/macrophages are present in the dorsal striatum at 2 (A–C) and 6 weeks (G–I) after MCAO. Neuroblasts were less frequent in
the ischemic striatal regions containing overactivated microglia/macrophages clustering (dorsal striatum), but intermingled with moderately activated
microglia in striatal regions outside microglia/macrophages clustering (ventral striatum). lv, lateral ventricle; st, striatum. Scale bar = 100 μm.
et al. 2012). The presence of alternative microglia in the CNS
is supported by recent investigations (Schwartz et al. 2006;
Thored et al. 2009).
Theideasdiscussedabovesuggestthatabeneﬁcialordetri-
mental microglial phenotype might be a direct consequence
ofwhichkindofPRRsareactivatedinadeterminedCNSdis-
ease. This idea raises a clear therapeutic implication. Which
microglial receptors are activated to induce neurodegener-
ation? Could they be experimentally blocked on microglia?
Recent studies suggest that speciﬁc blockage of PRRs (for
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example TLR4) and/or NADPH oxidase can be a promising
therapeutic approach for acute and chronic neural disor-
ders (Block et al. 2007; Skaper 2011). In addition, activa-
tion of NADPH oxidase seems to be a very important event
underlying the deleterious actions of microglia and experi-
mental inhibition of this enzyme induces signiﬁcant neuro-
protection (Block et al. 2007). Investigations on the intracel-
lular biochemical pathways responsible for both detrimental
and beneﬁcial actions of microglia are needed for develop-
ment of drugs, which are able to maximize microglial bene-
ﬁcial functions and antagonize the deleterious ones.
Theligandstriggeringtheparadoxicalactionsofmicroglia
after CNS diseases are unknown. Nevertheless, neuro-
melanin, α-synuclein, ﬁbrillar Aβ,A β, prion may play
a detrimental role on chronic neurodegenerative diseases
(Block et al. 2007). The nature of these ligands remains to
be determined after acute neural disorders, such as stroke
and brain/spinal cord trauma. Purine nucleotides (Davalos
et al. 2005), anti-inﬂammatory cytokines (Butovsky et al.
2005), and growth factors (Neumann et al. 1998) might be
potential candidates as beneﬁcial ligands.
Conclusion and Future Perspectives
In this paper, we shed light on the possible reasons by which
microglia can be both detrimental and beneﬁcial after CNS
diseases. We face microglia as the guardians of CNS, which
contribute to maintenance of its integrity in physiological
conditions. In pathological conditions, some microglial cells
might be affected by the disease process becoming overacti-
vatedcontributingtoneuronaldamage,whereasothersmight
maintain an intermediate (more physiological) level of acti-
vation contributing to neuronal rescue and repair processes.
This might be a consequence of the fact that both harmful
and beneﬁcial stimuli are released upon injury into speciﬁc
anatomical niches along the damaged areas triggering both
beneﬁcial and deleterious actions of microglia. Depending
ontheCNS-affectedareaanddisease’setiology,bothnoxious
andbeneﬁcialmicroglialphenotypesmightcoexistalongthe
pathological environment.
Further studies are necessary to characterize, both mor-
phologicallyandmolecularly,thedifferentanatomicalniches
of microglial activation after stroke and other neural dis-
orders. These studies must unravel the ligands that render
harmful and beneﬁcial microglial phenotypes as well as the
molecules released by activated microglia in both circum-
stances. In addition, these new experimental studies must
investigatetheeffectsofdrugsthatdonotcompletelyabolish
microglia activation, but rather modulate this phenomenon,
for example, avoiding clustering formation without interfer-
ing with physiological (beneﬁcial) levels of activation after
CNS diseases. It is also fundamental to ﬁnd out which mi-
c r o g l i ar e c e p t o r sa r es p e c i ﬁ c a l l ya c t i v a t e dt oi n d u c eb e n e ﬁ -
cial or detrimental actions after a CNS disease. Experimen-
tal manipulation of these receptors, and/or pharmacologi-
cal application of their beneﬁcial ligands, may be promising
therapeutic approaches used in the future for human neural
disorders.
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